Follow us on Twitter
twitter icon@FreshPatents


Autoimmune Disease patents

      

This page is updated frequently with new Autoimmune Disease-related patent applications.




 Marker sequences for diagnosing and stratifying sle patients patent thumbnailMarker sequences for diagnosing and stratifying sle patients
The present invention relates to methods for identifying markers for systemic lupus erythematosus (sle) and to the markers identified with the aid of this method, which can differentiate between sle and other autoimmune diseases on the one hand and between different sle subgroups on the other hand. The invention also relates to panels, diagnostic devices and test kits which comprise these markers, and to the use and application thereof, for example for the diagnosis, prognosis and therapy control in sle.
Protagen Ag


 Sequencing-directed selection of tumor theranostics patent thumbnailSequencing-directed selection of tumor theranostics
The present disclosure relates to therapies for the treatment of tumor, autoimmune diseases, or other diseases. In some embodiments, the present disclosure can relate to subject-specific selection of humanized antibodies targeting clonal lineage specific marker proteins..
Affigen, Inc.


 Method for identifying and validating dominant t helper cell epitopes using an hla-dm-assisted class ii binding assay patent thumbnailMethod for identifying and validating dominant t helper cell epitopes using an hla-dm-assisted class ii binding assay
Rational design of immunotherapeutics relies on clear knowledge of the immunodominant epitopes of antigens. Current methods for identifying kinetically stable peptide-mhc complexes are in many cases inadequate for a number of reasons.
The Johns Hopkins University


 Compositions of gm-csf and interleukin fusions for immune modulation and uses related thereto patent thumbnailCompositions of gm-csf and interleukin fusions for immune modulation and uses related thereto
This disclosure relates to recombinant proteins comprising a gm-csf sequence and an interleukin sequence and nucleic acids related thereto. In certain embodiments, the disclosure relates to recombinant proteins comprises n-terminal sequences that are the result of improved production techniques and uses for treating or preventing autoimmune diseases such as multiple sclerosis and cancer..
Children's Healthcare Of Atlanta, Inc.


 Suprametallogels and uses thereof patent thumbnailSuprametallogels and uses thereof
The disclosure provides nanostructures (e.g., nanospheres and nano-paddlewheels) formed through transition metal-ligand (e.g., pd(ii)-, ni(ii)-, or fe(ii)-ligand of formula (a)) coordination and junction self-assembly. The disclosure also provides supramolecular complexes that include the nanostructures connected by divalent linkers y.
Massachusetts Institute Of Technology


 Pharmaceutical composition comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis patent thumbnailPharmaceutical composition comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis
The present invention is related to the branch of immunology and particularly with the generation of pharmaceutical compositions containing a humanized monoclonal antibody recognizing the leukocyte differentiation antigen cd6. Accordingly with that statement, the purpose of this invention is to provide pharmaceutical compositions which contain a humanized anti-monoclonal antibody for the diagnosis and treatment of autoimmune diseases, particularly the rheumatoid arthritis..
Centro De Inmunologia Molecular


 Humanized anti-hla-dr antibodies patent thumbnailHumanized anti-hla-dr antibodies
The present invention concerns compositions and methods of use of humanized anti-hla-dr antibodies. In preferred embodiments, the antibodies induce apoptosis and inhibit proliferation of lymphoma cells without inducing cdc or adcc.
Immunomedics, Inc.


 Substituted amino triazoles useful as human chitinase inhibitors patent thumbnailSubstituted amino triazoles useful as human chitinase inhibitors
Disclosed are amino triazole compounds substituted with a piperidinyl ring that is itself substituted with a heterocyclic ring. These compounds are inhibitors of acidic mammalian chitinase and chitotriosidase.
Oncoarendi Therapeutics Sp. Z O.o.


 Indole carboxamide compounds patent thumbnailIndole carboxamide compounds
Or a salt thereof, wherein: x is cr4 or n; r1, r2, r3, r4, and a are defined herein. Also disclosed are methods of using such compounds as inhibitors of bruton's tyrosine kinase (btk), and pharmaceutical compositions comprising such compounds.

 Polyfluorinated compounds acting as bruton tyrosine kinase inhibitors patent thumbnailPolyfluorinated compounds acting as bruton tyrosine kinase inhibitors
Described herein is a novel series of multi-fluoro-substituted pyrazolopyrimidine compounds or salts thereof. These compounds are bruton's tyrosine kinase (btk) inhibitors.
Zhejiang Dtrm Biopharma Co. Ltd.


Methods for modulating immune responses during chronic immune conditions by targeting il-27 induced pathways

Described herein are novel compositions comprising il-27 or nfil-3 modulators (i e , inhibitors or activators), and methods using these agents for targeting cells, such as functionally exhausted or unresponsive immune cells, and modulating tim-3 activity or expression. These compositions, methods, and uses are useful for the treatment of chronic immune conditions, such as persistent infections, cancer, and autoimmune diseases..
The Brigham And Women's Hospital, Inc.

Macrocyclic therapeutic agents, methods of manufacture, and methods of treatment

The instant invention describes macrocyclic compounds having therapeutic activity, and the mechanism and methods of treating disorders such as autoimmune diseases, inflammation, and cancer, tumors and cell proliferation related disorders.. .
University Of Florida Research Foundation, Incorporated

Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Novel benzimidazoles according to formula i, able to inhibit jak are disclosed, these compounds may be prepared as a pharmaceutical composition, and may be used for the prevention and treatment of a variety of conditions in mammals including humans, including by way of non-limiting example, allergic diseases, inflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of il6 or hypersecretion of interferons.. .

Medicament for treating peripheral neuropathies

The invention provides a method for treatment of the diseases in a human by identifying the human as one suffering from a herpes simplex virus (hsv), and then administering to the human the compound anti-hsv agent or a pharmaceutically acceptable salt thereof. The diseases include dermatosis and non-dermatosis, wherein the dermatosis include acnes, impetigo, pyoderma gangrenosum, chilblains and psoriasiform, asteatotic dermatitis, ichthyosis, lichen simplex chronicus (neurodermatitis, prurigo), seborrhoeic dermatitis, rosacea, perioral dermatitis, epidermal cyst, wound ulcer, discoid lupus erythematosus, vitiligo, alopecia, diagnostic criteria of some autoimmune diseases such as systemic lupus erythematosus or diabetic skin complications, wherein the non-dermatosis include glomerulonephritis, arthritis, crohn's disease, ulcerative colitis, myelodysplasia, multiple myeloma, demyelinating disease, parkinson's disease, anemia, cytopenia those among the diagnostic criteria..

Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases

This disclosure provides new genetic targets, diagnostic methods, and therapeutic treatment regimens for multiple autoimmune disorders, including pediatric autoimmune disorders that are co-inherited and genetically shared. The disclosure, for example, provides methods of diagnosing or determining a susceptibility for one or more autoimmune diseases and methods of determining treatment protocols for patients with one or more autoimmune diseases based on determining if the patients have genetic alterations in particular genes..
The Children's Hospital Of Philadelphia

Methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway

The present invention relates to methods and pharmaceutical compositions for the treatment of diseases mediated by the nrp-1/obr complex signaling pathway. In particular, the present invention relates to a method for treating a disease selected from the group consisting of cancers, obesity and obesity related diseases, anorexia, autoimmune diseases and infectious diseases in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an antagonist of the nrp-1/obr signaling pathway..
Universite De Bourgogne

Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

This invention provides for a fusion protein between an il2αβγ selective agonist protein (il2 selective agonist) and a igg fc protein. The il2 selective agonist moiety provides a therapeutic activity by selectively activating the il2αβγ form of the receptor, thus selectively stimulating tregs.
Delinia, Inc.

Inhibitors of bruton's tyrosine kinase

Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
Pharmacyclics Llc

Methods of measuring antigen-specific t cells

Provided herein are methods and kits for assaying antigen-specific t cell responses, such as rare autoantigen-specific t cell responses, by measuring a level of ip-10 in a sample from a subject having or suspected of having an autoimmune disease, an allergy, an infectious disease or condition, or an adverse immune condition caused by administration of an isolated, recombinant or synthetic protein or peptide. Also provided herein are methods and kits for assaying a t cell response to an antigen peptide, such as an islet autoantigen peptide, such as measuring a t cell response to at least one antigen peptide, such as an islet autoantigen peptide, in a sample from a subject, such as one having or suspected of having type 1 diabetes (tid), celiac disease or both..
Immusant, Inc.

Methods for the diagnostic of an autoimmune disease

An in vitro method for determining whether a patient has, or is at risk of having or developing an autoimmune disease or for assessing the severity or predicting the outcome of an autoimmune disease, comprising a step of detecting or quantifying in a biological sample obtained from said patient an immune anti-il2 response, peptides specifically recognised by anti-il2 antibodies or il-2-specific t cells of t1d, systemic lupus erythematosus, rheumatoid arthritis, sjögren's syndrome and autoimmune polymyositis patients, and pharmaceutical compositions.. .
Universite Paris Descartes

Immunotherapy with binding agents

The present invention provides agents, such as soluble receptors, antibodies, and small molecules that modulate the immune response. In some embodiments, the agents activate or increase the immune response to cancer and/or a tumor.
Oncomed Pharmaceuticals

2,2'-tandem dithiazole compound, preparation method therefor, and use thereof

The present invention relates to a thiazole-based compound, a preparation method therefor, and a use thereof. More specifically, the present invention relates to a 2,2′-bis-thiazole-based compound, a preparation method therefor, and a use of 2,2′-bis-thiazole-based compound a histone deacetylase inhibitor in the preparation of an antitumor medicament, a medicament for treating autoimmune diseases, a medicament for treating type ii diabetes mellitus and complication thereof, or a medicament for treating neurodegenerative diseases..
Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences

Compositions having means for targeting at least one antigen to dendritic cells

A composition that can be used as a vaccine containing means for targeting at least one antigen to dendritic cells and as adjuvants a granulocyte macrophage colony stimulating factor and a cpg oligodeoxynucleotide and/or a cpg-like oligodeoxynucleotide. This composition can used to treat cancers, infectious diseases caused by bacterial, viral, fungal, parasitic or protozoan infections, allergies and/or autoimmune diseases..
Universite Paris Descartes

Substituted bicyclic compounds

And/or a salt thereof, wherein r1 is —oh or —op(o)(oh)2, and x1, x2, x3, r2, r2a, ra, rb, and rc are defined herein. Also disclosed are methods of using such compounds as selective agonists for g protein-coupled receptor s1p1, and pharmaceutical compositions comprising such compounds.

Elisa for a naturally-occurring soluble truncated form of il-23 receptor

A naturally-occurring soluble truncated il-23rα protein (i.e., Δ9 il-23rα) is shown to be present in a biological sample and can serve as a diagnostic tool for autoimmune diseases. There is provided an enzyme-linked immunosorbent assay (elisa) and test kit for the serological detection of the soluble truncated form of il-23rα protein.
Medical Diagnostic Laboratories, Llc

Cd8+ regulatory t-cells for use in the treatment of inflammatory and autoimmune diseases

The present invention relates to a method for identifying cd8+ treg cells suitable for use as starting material in cellular immunotherapy, the method comprising i) analysing samples from target tissue a to identify cd8+ treg cells with migratory character between the diseased tissue, collecting lymphatics, peripheral blood, distinct tissue adjacent to the diseased target tissue a and/or distinct tissue that is not vicinal though has migratory treg communication with target tissue a, v) analysing samples from peripheral blood, tissue c, to identify cd8+ treg cells with migratory character and/or functional character where the treg cells are also emigrant from target tissue a, vi) analysing sample(s) from tissue compartments a and/or b and c, that are analytically or physically depleted of emigrants from thymus and/or immigrants from peripheral blood to a lymph node, to restrict analyses to cd8+ treg cells of target tissue a origin and/or tropism, to identify emigrant cd8+ treg cell populations of target tissue a, to identify emigrant cd8+ treg cell populations with propensity to immigrate to target tissue a, to identify a migratory and/or functional defect in the cd8+ treg cell population identified as expressing migratory and/or functional elements specific for target tissue a in any of tissue a, b or c, and whereby a combination of surface or intracellular markers on cd8+ treg cells is identified, which combination identifies which surface or intracellular markers should be present and which surface markers should not be present in cd8+ treg cell populations suitable for use as starting material in cellular immunotherapy.. .
Genovie Ab

Method for the identification of cd4+ regulatory t-cells for use in the treatment of inflammatory and autoimmune diseases

The present invention relates to a method for identifying cd4+ treg cells suitable for use as starting material in cellular immunotherapy, the method comprising i) analysing samples from target tissue a to identify cd4+ treg cells with migratory in character between the diseased tissue, collecting lymphatics, peripheral blood, distinct tissue adjacent to the diseased target tissue a and/or distinct tissue that is not vicinal though has migratory treg communication with target tissue a, v) analysing samples from peripheral blood, tissue c, to identify cd4+ treg cells with migratory character and/or functional character where the treg cells are also emigrant from target tissue a, vi) analysing sample(s) from tissue compartments a and/or b and c, that are analytically or physically depleted of emigrants from thymus and/or immigrants from peripheral blood to a lymph node, to restrict analyses to cd4+ treg cells of target tissue a origin and/or tropism, to identify emigrant cd4+ treg cell populations of target tissue a, to identify emigrant cd4+ treg cell populations with propensity to immigrate to target tissue a, to identify a migratory and/or functional defect in the cd4+ treg cell population identified as expressing migratory and/or functional elements specific for target tissue a in any of tissue a, b or c, and whereby a combination of surface or intracellular markers on cd4+ treg cells is identified, which combination identifies which surface or intracellular markers should be present and which surface markers should not be present in cd4+ treg cell populations suitable for use as starting material in cellular immunotherapy.. .
Genovie Ab

Anti-human il-21 antibodies

Monoclonal antibodies are identified that bind the il-21 protein. These antibodies are used to identify regions of the il-21 protein to where binding neutralizes il-21 activity.
Zymogenetics, Inc.

Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases

This invention provides for a fusion protein between an il2αβγ selective agonist protein (il2 selective agonist) and a igg fc protein. The il2 selective agonist moiety provides a therapeutic activity by selectively activating the il2αβγ form of the receptor, thus selectively stimulating tregs.
Delinia, Inc.

Compounds and use thereof in the expansion of hematopoietic stem cells and/or hematopoietic progenitor cells

Compounds of general formula or salts or prodrugs thereof, are provided and described herein. The compounds are useful to expand hematopoietic stem cell and/or hematopoietic progenitor cell populations.
UniversitÉ De MontrÉal



Autoimmune Disease topics:
  • Autoimmune Disease
  • Immune Disease
  • Autoimmune
  • Autoimmune Diseases
  • Immune Diseases
  • Transplant
  • Infectious Disease
  • Infectious
  • Inflammatory Disease
  • Antagonist
  • Rheumatoid Arthritis
  • Proliferative
  • Nucleotide
  • Antibodies
  • Infectious Diseases


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Autoimmune Disease for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune Disease with additional patents listed. Browse our RSS directory or Search for other possible listings.


    0.154

    file did exist - 2937

    2 - 1 - 54